相关实验视频

Updated: Mar 13, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

急性髓性白血病患者FLT3突变的增加和损失:一个非干预性队列研究 (CLEVO)

Cristina Papayannidis¹, Irina Amitai², Pascal Turlure³

¹IRCCS Azienda Ospedaliero Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.

Oncology and therapy

|March 11, 2026

概括

在急性髓性白血病 (AML) 复发期间,FMS类型的氨酸激酶3 (FLT3) 突变状态发生变化. 基线FLT3阳性状态,不是第一次发生,与更好的结果相关,建议通过重新测试进行个性化治疗.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

类似FMS的铁酶3 (FLT3) 突变是急性髓性白血病 (AML) 的关键.
在复发性/耐药性AML中FLT3突变的检测性和克隆进化动态尚不清楚.
了解这些动态对于治疗策略至关重要.

研究的目的:

研究AML患者的克隆进化和结果,从诊断到复发/耐药性疾病.
分析疾病过程中FLT3突变状态的动态变化.
确定FLT3突变状态与患者结果之间的关联.

主要方法:

前性,非干预性研究设计.
包括650名AML患者.
在诊断和复发时分析FLT3突变状态,以及生存数据 (总体存活率,无病存活率,无事件存活率).

主要成果:

在疾病过程中,FLT3突变状态有所变化,FLT3阳性患者中有15.6%和FLT3阴性AML患者中有14.9%的患者经历了突变增益或损失.
在FLT3阳性患者中,整体存活期无法估计,但在FLT3阴性患者中为20.3个月.
无事件生存期为FLT3阳性患者17.2个月,FLT3阴性患者10.4个月.

结论:

在AML患者中,FLT3突变状态发生动态变化.
基线FLT3阳性状态,但不是第一次发生时,与改善的结果有关.
重新测试FLT3突变可能有助于个性化AML治疗.

关键词:

在FLT3突变中.在AML,AML就是AML.克隆的演化过程中的克隆进化.突变检测检测突变检测检测复发/耐药性疾病复发/耐药性疾病复发铁氨酸激酶酶是一种氨酸激酶.

更多相关视频

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Loss of Tumor Suppressor Gene Functions

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...